Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI (TM) algorithm for cardiac amyloidosis (CA) -- the first and only cleared ...
GlobalData on MSN
FDA approves Anumana’s pulmonary hypertension algorithm
The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data transfer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results